U.S. Donates 99,450 COVID-19 vaccines to Senegal

Press Release Shim

Speeches Shim

Man gets vaccinated against COVID-19 at a USAID-sponsored clinic
Man gets vaccinated against COVID-19 at a USAID-sponsored clinic
MTaPs

For Immediate Release

Tuesday, April 19, 2022

On April 19, 2022, thanks to the American people’s generosity and in partnership with COVAX and the African Union, Senegal received a donation of an additional 99,450 doses of Pfizer vaccine to assist in fighting COVID-19. These safe and effective vaccines will protect lives in Senegal and help prevent the spread of dangerous new variants.  

“The United States Government is committed to turning the tide on COVID-19,” stated USAID Mission Director Peter Trenchard. “We will continue to collaborate with our public health partners to make sure vaccines are available and accessible to populations across the world, including here in Senegal.”

This donation builds on the 1,840,530 doses of WHO-approved COVID-19 vaccines the United States has already provided to Senegal. In addition, the United States Agency for International Development (USAID) is supporting Senegal to safely and effectively distribute these vaccines by providing training to  health workers, getting vaccines where they need to go, and encouraging people to get vaccinated. 

USAID has worked closely with Senegal since the pandemic began to keep health workers safe with protective equipment such as masks and gloves, supplement Senegal’s oxygen supply, provide vaccine education, and support pop-up vaccination clinics.

Worldwide, the United States has pledged more than 1.2 billion vaccines and already delivered more than 524 million around the world as the largest donor to the global vaccine initiative, COVAX. 

The United States is committed to leading the global COVID-19 response because it is the right thing to do and will make us all—Americans and Senegal alike—safer. We are proud to work with Senegal to end this pandemic and build back a better world. 

Last updated: May 19, 2022

Share This Page